Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation by Reaney Matthew et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Health and Quality of Life Outcomes
Open Access Research
Impact of schizophrenia and schizophrenia treatment-related 
adverse events on quality of life: direct utility elicitation
Andrew Briggs1,2, Diane Wild*1, Michael Lees1, Matthew Reaney1, 
Serdar Dursun3, David Parry4 and Jayanti Mukherjee4
Address: 1Oxford Outcomes Ltd, Oxford, UK, 2Section of Public Health and Health Policy, University of Glasgow, Glasgow, UK, 3Neuroscience 
and Psychiatry Unit, The University of Manchester, Manchester, UK and 4Bristol-Myers Squibb Company, Uxbridge, UK
Email: Andrew Briggs - andrew.briggs@oxfordoutcomes.com; Diane Wild* - diane.wild@oxfordoutcomes.com; 
Michael Lees - michael.lees@bayerhealthcare.com; Matthew Reaney - matt.reaney@ahpresearch.com; Serdar Dursun - Dursun@ualberta.ca; 
David Parry - david.parry@bms.com; Jayanti Mukherjee - jayanti.mukherjee@bms.com
* Corresponding author    
Abstract
Objective: To examine the impact of schizophrenia, its treatment and treatment-related adverse
events related to antipsychotics, on quality of life from the perspective of schizophrenia patients
and laypersons.
Methods: Health state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS),
hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the
literature and expert opinion. The quality of life impact of each health state was elicited using a time
trade-off instrument administered by interview to 49 stable schizophrenia patients and 75
laypersons. Regression techniques were employed to examine the importance of subject
characteristics on health-related utility scores.
Results: Patients and laypersons completed the interview in similar times. Stable schizophrenia had
the highest mean utility (0.87 and 0.92 for laypersons and patients respectively), while relapse (0.48
and 0.60) had the lowest mean utility. Of the treatment-related adverse events, EPS had the lowest
mean utility (0.57 and 0.72, respectively). Age, gender and PANSS score did not influence the utility
results independently of health state. On average, patient utilities are 0.077 points higher than
utilities derived from laypersons, although the ranking was similar between the two groups.
Conclusion: Events associated with schizophrenia and treatment of schizophrenia can bring about
a significant detriment in patient quality of life, with relapse having the largest negative impact.
Results indicate that patients with stable schizophrenia are less willing to trade years of life to avoid
schizophrenia-related symptoms compared to laypersons. Both sets of respondents showed equal
ability to complete the questionnaire.
Background
Schizophrenia is a severe form of mental illness affecting
approximately 24 million people worldwide [1]. Clinical
management of schizophrenia is possible using a range of
different antipsychotics, although treatment is associated
with a variety of treatment-related adverse events. In order
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to capture the true impact of treatment benefit, it is impor-
tant to quantify not only the impact of the disease on
health-related quality of life, but also the impact of treat-
ment-related adverse events.
Previous studies investigating the impact of schizophrenia
on quality of life have focused on the different stages of
the disease and extra pyramidal symptoms (EPS) such as
akathesia, agitation, and tardive dyskinesia [2,3]. How-
ever, with the introduction of an increasing number of
atypical antipsychotics (such as aripiprazole, olanzapine,
risperidone and quetiapine), differences between treat-
ments related to adverse events, such as hyperprolactine-
mia and weight gain, are also important. One naturalistic
study shows clear differences in the incidence of these
adverse events between different atypicals, as well as dif-
ferences between typical and atypical antipsychotics [4].
Other research has shown that after adjustment for per-
sonal risk factors and concomitant drug-use, patients tak-
ing conventional or newer anti-psychotics have a
significantly increased risk of diabetes [5]. Such differ-
ences are potentially important drivers of the relative cost-
effectiveness of different antipsychotics for the treatment
of schizophrenia.
With the exception of EPS, the impact of these adverse
events and of treatment relapse on quality of life has not
been previously assessed. For health economic evaluation
health related utilities are the preferred method of meas-
uring health related quality of life with values ranging
from less than zero to 1, where zero represents death and
1 represents best possible health. The most commonly
used approach to eliciting utilities is the time trade-off
technique (TTO) [6] and this approach has also been
applied in schizophrenia [7]. When eliciting utilities for
use in health economic evaluation, the choice of whether
to elicit values direct from patients or from the lay popu-
lation is contentious [8]. On the one hand, patients have
direct experience of the disease and should therefore be
able to give a more informed response as to the burden of
health states that they have actually experienced. Layper-
sons, on the other hand, have no vested interests in one
particular disease and can be thought of as 'future
patients'. The National Institute for Health and Clinical
Excellence (NICE) in the UK, clearly recommends that the
utilities be elicited based on public preferences in its guid-
ance [9].
In order to be consistent with the NICE reference case, but
also to reflect the lack of agreement in the literature, in
this study we chose to elicit utilities directly from both lay
and patient groups using the time trade-off approach. By
doing so it was possible to assess how these two groups
compared in terms of ability to complete the exercise as
well as the utilities obtained for the disease itself and the
treatment related side-effects. In addition, we also admin-
istered the EQ-5D instrument to patients (EuroQol
Group, 1990) [10]. The EQ-5D is a descriptive instrument
that describes the health status of a patient and can be
used to obtain an indirect estimate of utility by employing
utility tariffs derived from a large scale lay population
sample using the TTO method (Dolan et al, 1997) [11].
Methods
Descriptions of the health states
Health state descriptions for each of the schizophrenia-
related symptoms and adverse events were developed to
form the basis of the utility elicitation. These health states
were developed and adapted according to the following
approach:
1. Symptoms and potential adverse events were identified
from a comprehensive review of the literature using
Medline, and Embase databases, by considering com-
ments on patient websites and in close consultation with
Dr. George Awad, Professor of Psychiatry, University of
Toronto. Health state descriptions were then developed
based on these symptoms and adverse events,
2. Cognitive interviews were conducted with ten patients
with schizophrenia. Cognitive interviews (Willis 1999)
[12] are designed to assess comprehension and the cogni-
tive processes undertaken by the respondent to answer a
question. There are two major sub-types of cognitive inter-
viewing methods: Think-aloud and verbal probing. This
study utilised a verbal probing approach to assess the
comprehensibility, clarity and relevance of the health
states to patients. Feedback was provided by patients on
the wording of the health states.
3. A cognitive debriefing study was also conducted with
ten laypersons to assess the comprehensibility and clarity
of the health state descriptions. Feedback was provided by
respondents on the wording of the health states.
4. Finalisation of the health states was based on the feed-
back provided by patients and lay respondents.
This approach ensured that the health state descriptions
were clinically relevant and meaningful and that health-
related utilities elicited from patients and laypersons
could be compared. Table 1 presents the final health state
descriptions. Although the quality of life impact of EPS
and relapse has been previously assessed [13-19] these
health states were included so that the comparison
between utilities for these and other health states was
based on the same sample.
Participant recruitment
Both laypersons (n = 75) and patients (n = 50) were
recruited to the study. Laypersons were recruited through
newspaper advertising in Yorkshire, Oxfordshire and Lon-Health and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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Table 1: Health State Descriptions for the TTO
Health State Description
Stable schizophrenia – No side-effects Base-Case Stable Conditiona
￿ I am in my mid-30's, living alone with no dependants.
￿ My condition puts some limits on my daily life including the necessity to take regular medication. I have 
no problems with self-care and am able to complete household chores, but I don't meet too many new 
people.
￿ I am able to work at a part-time paid or voluntary job.
￿ Sometimes I hear things that no one else hears. I think someone is calling my name but when I turn 
around, no one is there. The things they say aren't scary, like when I was really sick, they are just calling 
my name.
￿ Sometimes it feels like there are other people in my house that shouldn't be there, or that people go 
through my things without asking. I don't think about this most of the time though.
No consequences from the treatment
Weight gain side-effect Base-Case Stable Condition plus
Consequences from the treatment:
￿ In the last six months I have gained more than a stone in weight and it makes me pretty depressed as I 
find it very hard to lose weight by diet and exercise.
￿ The extra weight has restricted my mobility and breathing and made some of my clothes too tight.
￿ I am worried about my weight gain because I have heard that that this might cause diabetes, heart 
problems and make me lose a year or two off my life expectancy.
Diabetes side-effect Base-Case Stable Condition plus
Consequences from the treatment:
￿ Since taking treatment I have been diagnosed with diabetes – my doctor says that it may be due to my 
treatment.
￿ I have started to feel tired and need to urinate more often. I also seem to feel nauseous and get sick 
more often.
￿ My doctor told me to change my eating habits so I have a more balanced diet, as well as drinking a 
maximum of two alcoholic drinks per day and taking my oral medication – otherwise the diabetes could 
get worse.
￿ The doctors are also telling me to exercise a lot more than before. I need to always make sure that I 
have my medicine and something sweet with me in case I get dizzy or faint.
￿ I need to test my blood sugar levels every day by pricking my finger with a pin and putting the blood on 
a paper strip.
￿ My doctor told me about research showing people with diabetes might lose more than five years off life 
expectancy
Hyperprolactinemia side-effect (Male) Base-Case Stable Condition plus
Consequences from the treatment
￿ I feel less interested in sex and when I do have sex, it is not as good as it was before I started treatment
￿ My doctor tells me that there is also a good chance that my breasts will be bigger than other men's and 
that a little milk might sometimes come from them.
Hyperprolactinemia side-effect (Female) Base-Case Stable Condition plus
Consequences from the treatment
￿ I feel less interested in sex and when I do have sex, it is not as good as it was before I started treatment
￿ My doctor tells me that taking the treatment may make my periods not come when I think they will. 
The doctor also tells me that I might also have a little milk flow from my nipple when it shouldn't.
EPS side-effect Base-Case Stable Condition plus
Consequences from the treatment
￿ Since I started treatment it seems as though I don't have full control over my muscles.
￿ Often I feel that my muscles are quivering and I just can't seem to sit still, while other times it actually 
feels at though my muscles are undergoing spasms.
￿ Other times it seems as though my body is moving when I don't want it to, and I do things like thrusting 
my tongue, marching up and down on the spot and humming.
￿ Sometimes people say that I shuffle rather than walk, and that my face doesn't show any emotion.
Relapse ￿ My condition has forced me to go back to hospital for treatment, and not many people come to see me 
– not that I want to see anyone
￿ It depresses me that I seem to have gone back to where I started before treatment, it seems as though 
there was no point in taking all those medicines
￿ I am not able to work at the moment and I am worried that my employer will not want me back
￿ I hear people calling me names and telling me to do things, just like I did when I was really sick
￿ It feels like the other people in the hospital are watching me, and talking about me behind my back.
a Base-Case Stable condition refers to a Typical patient with stable schizophreniaHealth and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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don in May and June 2005 and represented a convenience
sample. Fifty adult outpatients with a diagnosis of schizo-
phrenia or schizoaffective disorder (according to DSM-IV
guidelines) who were experiencing stable symptoms were
recruited to the study from Cromwell Community Mental
Health Centre, Manchester.
The choice of an outpatient 'stable schizophrenia' popula-
tion was selected based on previous studies in schizophre-
nia, and ensured that participation in the study did not
compromise the patients' well-being [7,17]. The stability
of potential participants was judged by the supervising cli-
nician (and confirmed by a total Positive and Negative
Syndrome Scale (PANSS) [20] score ≤ 70 during the inter-
view) on the day of the interview. Ethics approval for
patient involvement was gained from the Bolton Local
Research Ethics Committee in February 2005, and the
study was conducted in one-to-one interviews. Standard
ethically approved procedures were applied to obtain con-
sent where patients were asked to read the patient infor-
mation sheet and were asked to sign the consent form if
they were happy to participate in the study.
Utility interview
Laypersons
After completing a demographic form, the 75 laypersons
(a) read a short passage explaining schizophrenia and (b)
viewed a DVD that explained the impact of schizophrenia
on a person's life. The DVD showed an interview between
a psychologist and a stable schizophrenic patient [21].
The patient is able to articulately recall the effect schizo-
phrenia had on her life during acute exacerbations, and
the symptoms that she still experiences.
A trained interviewer then asked subjects to complete a
rating scale (visual analogue scale) where each health state
is ranked along the preference assessment rating scale
between scores of 100 (best possible health state) and 0
(worst possible health state). The rating scale was admin-
istered as an introductory task to familiarise respondents
with the health states, as suggested by Torrance et al. [22],
rather than to compare against utilities derived from the
TTO. After completing the rating scale participants com-
pleted the TTO for each health state. Health states were
presented in random order to ensure that results were not
influenced by the order of presentation.
Each health state description was presented to the
respondent. The interviewer offered a choice between
spending 30 years in that state followed by death (Alter-
native 1), or 29 years with perfect health followed by
death (Alternative 2). A 30-year time frame reflects the
average life expectancy of schizophrenia patients in the
hypothetical health state descriptions. If subjects chose to
spend 30 years in the health state being valued, they were
then asked to choose between 30 years in that health state
(Alternative 1), followed by death, or 1 year in perfect
health followed by death (Alternative 2). This is known as
the 'ping-pong method' [23] and is a standard approach
to health-related utility elicitation. The process continued
until the respondent was indifferent between spending 30
years in the particular health state and the number of years
being offered in perfect health. This process was repeated
for each health state being valued.
Patients
The 50 patients self-completed a demographic form and
the EQ-5D utility questionnaire to assess the health-
related utility of the patient for the day of the interview
[10]. The EQ-5D questionnaire produces answers to five
questions. This combination of answers, which provides
the patient mapped functionality of their current condi-
tion, then maps to a utility score that has been generated
from a UK lay population [11]. The result of this question-
naire provides an important validation of the baseline
health state – stable schizophrenia – described in this
study.
Clinical data (relating to the patients' medical history)
were also collected and a trained mental health nurse
administered the PANSS interview to assess the level of
the patients' symptomatology. One patient with a PANSS
score of 83 was excluded from further analysis. A trained
interviewer then administered the same interview to the
49 remaining patients to elicit TTO utilities for the differ-
ent health states exactly as was described above for the lay
sample.
Statistical methods
Mean utility scores from the TTO method [22] and stand-
ard deviations/errors were calculated for each health state.
In addition, a random effects regression analysis was per-
formed where random effects controlled for repeated
measures on the same subjects valuing different health
states. The regression was used to determine whether
patients and laypeople report different utility values, and
to determine whether utility values are explained by the
demographics of the lay sample or the PANSS score for the
patient sample. Potential explanatory variables that were
not significant predictors of utility score were omitted
from the regression analysis on the grounds of parsimony,
but only after applying a test of joint significance of
excluded variables. Robust standard errors were reported
in order to account for heteroskedasticity. All regression
analyses were performed using STATA 8.0.
Results
The study sample consisted of 75 laypersons and 49
patients which makes it the largest utility study to date in
this disease area. All patients and laypersons completedHealth and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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the utility interview. Demographic characteristics are pre-
sented in Table 2. As would be expected, people with
schizophrenia appear to have problems holding down
employment: 62% percent of the lay sample was in full-
time or part-time paid work opposed to only 8% of the
patient population. Patients were also more likely to be
single and have achieved a lower educational attainment.
Seventy percent of patients were diagnosed with paranoid
schizophrenia and a further 27% diagnosed with
schizoaffective disorder. Olanzapine, quetiapine and
clozapine were the most commonly prescribed antipsy-
chotic medications, although patients were often treated
using more than one antipsychotic. Total PANSS scores
range between 30 and 64. Patients were diagnosed
between the ages of 15 and 51, with the mean age of diag-
nosis 25.9 years (SD = 7.59).
The mean time taken to complete the utility interview was
26 minutes for both the lay and patient samples. Utilities
derived using the time trade-off approach are presented
for both patients and laypersons in Table 3. These show
that laypersons and patients both view relapse and EPS as
being the least desirable health states in which to spend
time, followed by diabetes. There is little difference
between the utilities associated with time spent with
hyperprolactinemia or weight gain, and the ordering of
these symptoms is reversed between patients and layper-
sons. The stable disease state was considered to have the
highest utility by both groups.
Table 3 also shows patients reporting significantly higher
utilities (p  < 0.05) for stable schizophrenia, EPS and
relapse than laypersons, while there are near significant
differences for weight gain and diabetes. However, a joint
assessment of the overall differences between results from
the patient and lay populations should take into account
the repeated utility measurement from individual sub-
jects. Table 4 therefore presents the results of two multiple
regressions, which shows the impact of each health state,
gender, age and respondent group (patients or laypeople)
on the utility value. The constant term represents the util-
ity associated with stable schizophrenia valued by a lay-
person and coefficients reported represent changes in
utility relative to this value.
It is clear from the first regression model that age and gen-
der have no significant influence on the utility and these
were therefore excluded from the model (having estab-
lished they were not jointly significant). The resulting
model shows that, on average, patient utilities are 0.077
points higher than utilities derived from laypeople. These
results also show that time spent in the relapse and EPS
states is associated with reductions in utility of 0.358 and
0.256 points, respectively.
An additional regression analysis was performed for the
patient sample only, including PANSS score as a predictor.
The results showed no evidence that the PANSS score had
any influence on the utility score reported by patients,
although the power of this test is reduced by the reduction
in sample size related to restricting the regression to just
49 patients.
The mean utility associated with the patient population's
current state of health, as measured by the EQ-5D, was
0.86. This health-related utility value is lower than the
utility for stable schizophrenia elicited directly from the
patient population (0.92), but almost identical to the util-
Table 2: Population Characteristics
Characteristic Layperson Sample Patient Sample
Total number (n) 75 49
Male/Female (n) 35/40 22/27
Mean age (years) 39.4 (17–76) 43.5 (21–64)
White ethnicity (%) 93.3% 93.9%
Marital Status
Single 21.3% 51.0%
Married 65.3% 30.6%
Cohabiting 8.0% 12.2%
Divorced 2.7% 2.0%
Widowed 2.7% 4.1%
Highest educational level
Did not complete high school 1.3% 28.6%
Minimum school age (GCSE's) 24.0% 59.2%
A-Levels 10.7% 8.2%
Degree or equivalent qualification 52.0% 4.1%
MSc Degree/PhD 12.0% 0%Health and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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ity for stable schizophrenia elicited from the lay popula-
tion (0.865).
Discussion
This study has demonstrated two important results.
Firstly, that stable schizophrenia has the lowest impact on
quality of life (highest utility value) and 'relapse' has the
highest impact on quality of life (lowest utility value) of
the health states measured. This is unsurprising, as these
two states represent the extremes in schizophrenia-related
health effects. The results also consistently showed 'EPS'
to have the second-greatest impact on quality of life, fol-
lowed by diabetes, while there was little difference
between the quality of life impacts of 'weight gain', and
'hyperprolactinemia'.
Table 3: Time trade-off utilities for lay and patient samples
Health State Mean utility (standard error) T-test for difference*
Patient sample Lay sample
Stable schizophrenia 0.919 (0.023) 0.865 (0.021) p = 0.087
Weight gain 0.825 (0.028) 0.779 (0.024) p = 0.216
Diabetes 0.769 (0.036) 0.712 (0.028) p = 0.215
Hyperprolactinemia 0.815 (0.030) 0.783 (0.025) p = 0.415
Relapse 0.604 (0.042) 0.479 (0.033) p = 0.022
EPS 0.722 (0.037) 0.574 (0.032) p = 0.003
*Unequal variance t-test
Table 4: Determinants of utility values
Explanatory variable Coefficient (standard error) – Unrestricted regression Coefficient (standard error) – Parsimonious regression
Constant 0.794 (0.062)* 0.856 (0.021)*
Weight gain - 0.090 (0.021)* - 0.089 (0.015)*
Diabetes - 0.151 (0.021)* - 0.151 (0.019)*
Hyperprolactinemia - 0.087 (0.021)* - 0.089 (0.014)*
Relapse - 0.355 (0.021)* - 0.358 (0.025)*
EPS - 0.256 (0.021)* - 0.256 (0.022)*
Patients 0.071 (0.034)* 0.077 (0.033)*
Age 0.002 (0.001) na
Female - 0.039 (0.033) na
Diagnostic parameters (unrestricted regression):
Number of observations = 738.
R2 (within) = 0.3871; R2 (between) = 0.0726; R2 (overall) = 0.2339.
Wald chi2(8) = 394.56.
Prob > chi2 < 0.0001.
Joint significance test on "Age" and "Female": chi2(2) = 3.81; Prob > chi2 = 0.1492
Diagnostic parameters (parsimonious regression):
Number of observations = 738.
R2 (within) = 0.3891; R2 (between) = 0.0424; R2 (overall) = 0.2215.
Wald chi2(6) = 397.18.
Prob > chi2 < 0.0001Health and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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The second key result is that the actual utility values varied
considerably according to the population from which the
values were derived. Utilities derived from patients were,
on average, 0.077 points higher than those derived from
the lay population. This indicates that patients are less
willing to trade years of life to avoid schizophrenia-related
health states. This is likely to be the result of a shift in psy-
chological expectations, which includes a shift in the
weight placed on different aspects of quality of life and a
changed view of what matters in life. General population
respondents are less likely to understand these shifts,
tending to focus on the transition to the state rather than
its longer term consequences, and therefore underesti-
mate the ability of a patient experiencing the disease to
adapt to their health state [8,24]. Other research indicates
that general population respondents focus more on the
negative aspects of a health state than the remaining pos-
itive aspects [25]. Together, these would lead to lower util-
ity values from the general population than a patient
population. These general observations, support schizo-
phrenia-specific work that has pointed to the importance
of self-experience and a model of recovery in this disease
[26,27] which supports the general concept of adaptation.
The study results confirms the earlier work of Voruganti et
al. [7] and Adams et al. [28] suggesting that stable patients
are capable of participating in studies designed to elicit
the quality of life impact of schizophrenia and its treat-
ment. Despite differences in utility values, patients and
laypersons took the same amount of time to complete the
interview and interviewers reported no problems in
understanding of the study tasks among either popula-
tion. It is important in health services research to gain the
perspectives of all participants, and this study shows that
a well-designed, sensitively administered interview is able
to elicit health-related utilities from patients as well as lay-
persons that can be used to inform decision makers about
the quality of life impact of schizophrenia. It is likely that
differences in the results reflect differences in perspective,
rather than an inability of patients to provide appropriate
responses.
The key potential problems in any health-related utility
study (which limits the transferability of results) relate to
the description of the health states and time period used
as the benchmark in the time trade-off procedure. In the
current study, the health state descriptions were devel-
oped after review of the published literature and consulta-
tion with clinical experts, and finalised following pilot
studies with both patients and lay groups. Further, the
mean utility values for stable disease – at 0.919 for
patients and 0.865 for laypeople – were higher than
hypothesised. However, the result from the EQ-5D
patient scores was very similar to the utility for stable dis-
ease among laypeople. As noted previously, the utilities
derived from EQ-5D scores are based on lay values.
Hence, the similarity of the two results indicates that lay-
people value the patient mapped functionality of their
condition from EQ-5D at a very similar level to how lay-
people value the stable schizophrenia health state
described in Table 1. This provides a good indication that
the health state descriptions are consistent with clinical
reality and mitigates any concerns over the use of a con-
venience sample of laypersons in this study.
This study was designed to assess the impact on quality of
life of key adverse events associated with the newer antip-
sychotics. Previous studies had shown that schizophrenia
relapse has a substantial impact on quality of life, as does
EPS. These results were supported in this study. However
the adverse events primarily associated with the newer
antipsychotics – hyperprolactinemia, weight gain and dia-
betes – have a lower impact on quality of life than EPS and
relapse. There are two ways in which adverse events such
as hyperprolactinemia, weight gain and diabetes – with
the lower measured impact on quality of life – can affect
the results of an economic evaluation. Firstly, such events
are likely to influence the desire of patients and their fam-
ilies to continue with medication, and may cause patients
to discontinue, with the associated increase in relapse.
This would ensure that more time was spent in the relapse
state with its substantial impact on quality of life. Sec-
ondly, the duration of these adverse events is also impor-
tant. The impact of relapse on quality of life is substantial
but relapse is a relatively transitory condition. Conversely,
weight gain and diabetes show a smaller impact on qual-
ity of life than relapse, but are more sustained. The overall
net effect of these quality of life differences could be deter-
mined through the use of the commonly employed out-
come measure in health economic evaluations: the
Quality Adjusted Life Year (QALY) which takes into
account both the quality of life effects and the duration of
that effect.
There are two main implications that flow from the results
reported here. Firstly, that treatment-related adverse
events all have a measurable impact on a patient's quality
of life. While EPS and relapse have the greatest impact on
quality of life, events such as hyperprolactinemia, weight
gain and diabetes noticeably reduce patient quality of life
compared with schizophrenia patients who do not suffer
from these adverse events. These results offer the potential
to minimise the net effect of disease and treatment on
patient quality of life and quality-adjusted life years in
economic analyses. Secondly, that the differences in valu-
ations provided between patients and lay persons can be
substantial in a disease such as schizophrenia and this
could impact the cost-effectiveness of different treatment
options for patients. Only by employing the sorts of esti-
mates provided in this study in future cost-effectivenessHealth and Quality of Life Outcomes 2008, 6:105 http://www.hqlo.com/content/6/1/105
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models can the potential importance of these differences
be fully determined.
Conclusion
In conclusion, there were clear differences between
patient and layperson responses to the utility question-
naire. However, the preference ordering of these health
states was similar, with stable schizophrenia having the
lowest impact on quality of life and relapse and EPS the
greatest impact on quality of life, indicating as clear an
understanding by patients of the health states and their
impact on quality of life as by laypersons. In a disease
such as schizophrenia, chronic side-effects of treatment
such as weight gain and diabetes may have just as large an
impact on QALYs as the acute symptoms of the condition
itself.
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